Related Experiment Video
Updated: Jul 12, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
1-Year Outcomes of Transcatheter Edge-to-Edge Repair in Anatomically Complex Degenerative Mitral Regurgitation
Robert L Smith1, D Scott Lim2, Linda D Gillam3
1Baylor Scott and White: The Heart Hospital Plano, Plano, Texas, USA.
Insights
Transcatheter edge-to-edge repair using the PASCAL system is safe and effective for high-risk patients with degenerative mitral regurgitation. One-year results show significant improvement in heart function and quality of life.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Devices
Background:
- The CLASP IID Registry evaluated the Edwards PASCAL transcatheter valve repair system.
- Transcatheter edge-to-edge repair (TEER) is an option for degenerative mitral regurgitation (DMR) in patients unsuitable for surgery.
Purpose of the Study:
- To assess the 1-year safety and clinical outcomes of TEER with the PASCAL system.
- To evaluate echocardiographic, functional, and quality-of-life improvements in patients with complex mitral valve anatomy and prohibitive surgical risk.
Main Methods:
- Prospective enrollment of 98 patients with severe DMR (3+ or 4+) and complex anatomy.
- Assessment of safety, echocardiographic parameters, and clinical endpoints at 1 year post-procedure.
- Oversight by a central screening committee, echocardiographic core laboratory, and clinical events committee.
Main Results:
- One-year Kaplan-Meier estimates for freedom from major adverse events, all-cause mortality, and heart failure hospitalization were 83.5%, 89.3%, and 91.5%, respectively.
- Significant reduction in mitral regurgitation (MR) was observed, with 93.2% achieving MR ≤2+ and 57.6% achieving MR ≤1+.
- Substantial improvements in New York Heart Association (NYHA) functional class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores were noted.
Conclusions:
- The PASCAL system demonstrated safety and efficacy in reducing MR at 1 year in high-risk patients.
- Continued improvements in clinical, echocardiographic, functional, and quality-of-life outcomes highlight the PASCAL system's value.
- TEER with the PASCAL system is a viable treatment option for severe DMR in patients with complex anatomy and prohibitive surgical risk.
Background:
Favorable 6-month outcomes from the CLASP IID Registry (Edwards PASCAL transcatheter valve repair system pivotal clinical trial) demonstrated that mitral valve transcatheter edge-to-edge repair with the PASCAL transcatheter valve repair system is safe and beneficial for treating prohibitive surgical risk degenerative mitral regurgitation (DMR) patients with complex mitral valve anatomy.
Objectives:
The authors sought to assess 1-year safety, echocardiographic and clinical outcomes from the CLASP IID Registry.
Methods:
Patients with 3+ or 4+ DMR who were at prohibitive surgical risk, had complex mitral valve anatomy based on the MitraClip Instructions for Use, and deemed suitable for treatment with the PASCAL system were enrolled prospectively. Safety, clinical, echocardiographic, functional, and quality-of-life outcomes were assessed at 1 year. Study oversight included a central screening committee, echocardiographic core laboratory, and clinical events committee.
Results:
Ninety-eight patients were enrolled. One-year Kaplan-Meier (KM) estimates of freedom from composite major adverse events, all-cause mortality, and heart failure hospitalization were 83.5%, 89.3%, and 91.5%, respectively. Significant mitral regurgitation (MR) reduction was achieved at 1 year (P < 0.001 vs baseline) including 93.2% at MR ≤2+ and 57.6% at MR ≤1+ with improvements in related echocardiographic measures. NYHA functional class and Kansas City Cardiomyopathy Questionnaire score also improved significantly (P < 0.001 vs baseline).
Conclusions:
At 1 year, treatment with the PASCAL system demonstrated safety and significant MR reduction, with continued improvement in clinical, echocardiographic, functional, and quality-of-life outcomes, illustrating the value of the PASCAL system in the treatment of prohibitive surgical risk patients with 3+ or 4+ DMR and complex mitral valve anatomy.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation I: Introduction
Mitral Stenosis III: Medical Management
Mitral Regurgitation IV: Nursing Management
Mitral Stenosis II: Clinical features and Diagnostic Tests

